Promise of personalized omics to precision medicine
暂无分享,去创建一个
[1] A. Y. Lu,et al. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine , 2011, Pharmacological Reviews.
[2] Inyoul Lee,et al. Extracellular microRNA: a new source of biomarkers. , 2011, Mutation research.
[3] Euan A Ashley,et al. Performance comparison of whole-genome sequencing platforms , 2011, Nature Biotechnology.
[4] C. Newgard. Interplay between lipids and branched-chain amino acids in development of insulin resistance. , 2012, Cell metabolism.
[5] J. Barrett,et al. Genetic risk prediction in complex disease , 2011, Human molecular genetics.
[6] Andrew C. Adey,et al. Haplotype-resolved genome sequencing of a Gujarati Indian individual , 2011, Nature Biotechnology.
[7] John C Lindon,et al. Pharmacometabonomics as an effector for personalized medicine. , 2011, Pharmacogenomics.
[8] Y. Louzoun,et al. Rep‐Seq: uncovering the immunological repertoire through next‐generation sequencing , 2012, Immunology.
[9] Jan Tavernier,et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors , 2011, Nature Medicine.
[10] C. Mayr,et al. Widespread Shortening of 3′UTRs by Alternative Cleavage and Polyadenylation Activates Oncogenes in Cancer Cells , 2009, Cell.
[11] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[12] T. Hankemeier,et al. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? , 2006, Pharmacogenomics.
[13] A. Barabasi,et al. Systems biology and the future of medicine , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.
[14] Huanming Yang,et al. Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm , 2012, Cell.
[15] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[16] Richard B. Schwab,et al. Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens , 2012, Nucleic acids research.
[17] David T. W. Jones,et al. Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations , 2012, Cell.
[18] Alexander A. Morgan,et al. Type 2 Diabetes Risk Alleles Demonstrate Extreme Directional Differentiation among Human Populations, Compared to Other Diseases , 2012, PLoS genetics.
[19] Richard M Caprioli,et al. A Novel Histology-directed Strategy for MALDI-MS Tissue Profiling That Improves Throughput and Cellular Specificity in Human Breast Cancer* , 2006, Molecular & Cellular Proteomics.
[20] Joseph B. Martin. Huntington's disease , 1984, Neurology.
[21] M. Gerstein,et al. The Transcriptional Landscape of the Yeast Genome Defined by RNA Sequencing , 2008, Science.
[22] Y. Lee,et al. Gene-Gene and Gene-Environmental Interactions of Childhood Asthma: A Multifactor Dimension Reduction Approach , 2012, PloS one.
[23] V. Hu,et al. A systems approach towards an understanding, diagnosis and personalized treatment of autism spectrum disorders. , 2011, Pharmacogenomics.
[24] Mark Gerstein,et al. Personal phenotypes to go with personal genomes , 2009, Molecular systems biology.
[25] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[26] Hanlee P. Ji,et al. Corrigendum: Performance comparison of whole-genome sequencing platforms , 2012, Nature Biotechnology.
[27] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[28] A. Darzi,et al. Gut microbiome-host interactions in health and disease , 2011, Genome Medicine.
[29] L. Langman,et al. The challenges of personalized medicine. , 2012, Clinical biochemistry.
[30] Giovanni Parmigiani,et al. The Predictive Capacity of Personal Genome Sequencing , 2012, Science Translational Medicine.
[31] Kevin Y. Yip,et al. Extensive In Vivo Metabolite-Protein Interactions Revealed by Large-Scale Systematic Analyses , 2010, Cell.
[32] Aravinda Chakravarti,et al. Genomics Is Not Enough , 2011, Science.
[33] Huanming Yang,et al. Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor , 2012, Cell.
[34] Stephen L. Hauser,et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis , 2010, Nature.
[35] David R. Murdock,et al. Whole-Genome Sequencing for Optimized Patient Management , 2011, Science Translational Medicine.
[36] A. Barabasi,et al. The human disease network , 2007, Proceedings of the National Academy of Sciences.
[37] Mark Gerstein,et al. Personal genome sequencing: current approaches and challenges. , 2010, Genes & development.
[38] E. Birney,et al. A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.
[39] Linfeng Wu,et al. Overcoming the dynamic range problem in mass spectrometry-based shotgun proteomics , 2006, Expert review of proteomics.
[40] Mingyao Li,et al. Widespread RNA and DNA Sequence Differences in the Human Transcriptome , 2011, Science.
[41] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[42] Steven P Gygi,et al. The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry , 2008, Nature Protocols.
[43] F. Mazzocchi. Complexity and the reductionism–holism debate in systems biology , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.
[44] Euan A Ashley,et al. A public resource facilitating clinical use of genomes , 2012, Proceedings of the National Academy of Sciences.
[45] Muin J Khoury,et al. A population approach to precision medicine. , 2012, American journal of preventive medicine.
[46] Alexander A. Morgan,et al. Clinical assessment incorporating a personal genome , 2010, The Lancet.
[47] Jessica C. Ebert,et al. Accurate whole genome sequencing and haplotyping from10-20 human cells , 2012, Nature.
[48] A. Ashworth,et al. A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers , 2012, The Journal of pathology.
[49] L. Mucke,et al. Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.
[50] P. D. Rijk,et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing , 2011, Nature Biotechnology.
[51] S. Kaufman. Correction for Kaufman, A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients , 1999, Proceedings of the National Academy of Sciences.
[52] L. Hood,et al. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. , 2012, New biotechnology.
[53] Alexander A. Morgan,et al. Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes , 2012, Proceedings of the National Academy of Sciences.
[54] On beyond GWAS , 2010, Nature Genetics.
[55] M. Gerstein,et al. RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.
[56] G. Omenn,et al. Evolution of Translational Omics: Lessons Learned and the Path Forward , 2013 .
[57] F. Real,et al. An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity , 2012, Proteomics.
[58] David J. Elliott,et al. Alternative splicing and biological heterogeneity in prostate cancer , 2009, Nature Reviews Urology.
[59] Juliane C. Dohm,et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.
[60] L. Smarr. Quantifying your body: a how-to guide from a systems biology perspective. , 2012, Biotechnology journal.
[61] M. DePamphilis,et al. HUMAN DISEASE , 1957, The Ulster Medical Journal.
[62] P. Shannon,et al. Analysis of Genetic Inheritance in a Family Quartet by Whole-Genome Sequencing , 2010, Science.
[63] Hidenori Ojima,et al. High-resolution characterization of a hepatocellular carcinoma genome , 2011, Nature Genetics.
[64] N. Cho,et al. In situ identification and localization of IGHA2 in the breast tumor microenvironment by mass spectrometry. , 2012, Journal of proteome research.
[65] Russ B. Altman,et al. Bioinformatics challenges for personalized medicine , 2011, Bioinform..
[66] John R. Yates,et al. The biological impact of mass-spectrometry-based proteomics , 2007, Nature.
[67] Massimo Loda,et al. Investigative pathology: leading the post-genomic revolution , 2012, Laboratory Investigation.
[68] J. Nielsen,et al. Nutritional systems biology: definitions and approaches. , 2009, Annual review of nutrition.
[69] Tom Royce,et al. A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.
[70] M. Gerstein,et al. Dynamic transcriptomes during neural differentiation of human embryonic stem cells revealed by short, long, and paired-end sequencing , 2010, Proceedings of the National Academy of Sciences.
[71] Neema Jamshidi,et al. Individualized therapy of HHT driven by network analysis of metabolomic profiles , 2011, BMC Systems Biology.
[72] Julian L. Griffin,et al. Metabolic profiles of cancer cells , 2004, Nature Reviews Cancer.
[73] N. Serkova,et al. Metabolomics of cancer. , 2009, Methods in molecular biology.
[74] Omar E. Cornejo,et al. Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence , 2011, PLoS genetics.
[75] Dmitry Pushkarev,et al. Single-molecule sequencing of an individual human genome , 2009, Nature Biotechnology.
[76] Ara Darzi,et al. Preparing for precision medicine. , 2012, The New England journal of medicine.
[77] Joseph Loscalzo,et al. Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.
[78] M. Dietel,et al. Personalized cancer medicine and the future of pathology , 2011, Virchows Archiv.
[79] Hugo Y. K. Lam,et al. Performance comparison of exome DNA sequencing technologies , 2011, Nature Biotechnology.
[80] James Taylor,et al. Next-generation sequencing data interpretation: enhancing reproducibility and accessibility , 2012, Nature Reviews Genetics.
[81] S. Brahmachari,et al. Pharmacogenomics: a path to predictive medicine for schizophrenia. , 2006, Pharmacogenomics.
[82] Trey Ideker,et al. Boosting Signal-to-Noise in Complex Biology: Prior Knowledge Is Power , 2011, Cell.
[83] Lee E. Edsall,et al. Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.
[84] Hugo Y. K. Lam,et al. Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.
[85] Li Ding,et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. , 2011, JAMA.
[86] O. Delattre,et al. Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer , 2008, Proceedings of the National Academy of Sciences.
[87] Jared C. Roach,et al. Chromosomal haplotypes by genetic phasing of human families. , 2011, American journal of human genetics.